Arsenic derivatives in hematologic malignancies: a role beyond acute promyelocytic leukemia?
Article first published online: 19 JUN 2006
Copyright © 2006 John Wiley & Sons, Ltd.
Volume 24, Issue 4, pages 181–188, December 2006
How to Cite
Verstovsek, S., Giles, F., Quintás-Cardama, A., Perez, N., Ravandi-Kashani, F., Beran, M., Freireich, E. and Kantarjian, H. (2006), Arsenic derivatives in hematologic malignancies: a role beyond acute promyelocytic leukemia?. Hematol. Oncol., 24: 181–188. doi: 10.1002/hon.787
- Issue published online: 1 DEC 2006
- Article first published online: 19 JUN 2006
- Manuscript Accepted: 8 MAY 2006
- Manuscript Revised: 14 APR 2006
- Manuscript Received: 22 FEB 2006
- arsenic trioxide;
- hematologic malignancies;
- organic arsenic derivatives;
The importance of arsenic trioxide (As2O3) has been underscored over the last decade due to its efficacy against acute promyelocytic leukemia (APL), a disease in which this agent has been associated with complete hematologic and molecular remission rates of 87% and 83%, respectively. The different molecular mechanisms of action of As2O3 suggest its applicability in hematologic malignancies other than APL. However, responses obtained thus far have consisted of improvements in signs and symptoms without the elimination of a given disease. Toxicities derived from As2O3 are significant but manageable and reversible. However, the risk/benefit ratio of As2O3 in hematologic malignancies other than APL is still unclear. The development of new generations of orally bioavailable inorganic, as well as new organic, arsenic compounds with improved toxicity profiles may bolster the therapeutic application of arsenic derivatives in hematologic malignancies such as leukemia, multiple myeloma and myelodysplastic syndromes. Copyright © 2006 John Wiley & Sons, Ltd.